Imovane

Zopiclone, the active ingredient in Imovane, is a cyclopyrrolone (non‑benzodiazepine hypnotic) presented as an oral tablet for oral use. It is prescribed to manage insomnia in adults by helping patients fall asleep and maintain sleep throughout the night.

GNH USA supplies Imovane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zopiclone is used as a sedative/hypnotic for the treatment of sleep disorders.

Insomnia (sleep onset): facilitates falling asleep quickly. Insomnia (sleep maintenance): reduces nighttime awakenings. Short‑term sleep disturbance: provides temporary relief of difficulty sleeping.

Common Side Effects: - Drowsiness - Dry mouth - Headache - Dizziness - Taste disturbance - Nausea

Serious or Rare Side Effects: - Complex sleep behaviours (e.g., sleepwalking, sleep‑driving) - Severe allergic reactions (rash, swelling, anaphylaxis) - Marked memory impairment or amnesia - Mood changes or depression - Respiratory depression in susceptible individuals

Before prescribing Imovane, clinicians should consider several safety factors. - Assess renal function: adjust use in severe impairment. - Avoid alcohol: may increase sedation and respiratory depression. - Use only short term: limit treatment to 2–4 weeks to reduce dependence risk. - Monitor for dependence: discontinue gradually under medical supervision. - Pregnancy and lactation: consult a physician before use. - Store at ambient temperature: keep in original container, protect from moisture and light.

Zopiclone may interact with other substances that depress the central nervous system.

Major Interactions (Avoid): - Alcohol: additive CNS depression and increased sedation. - Opioids: heightened risk of respiratory depression. - Other CNS depressants (e.g., benzodiazepines, antihistamines): enhanced sedative effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations. - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect. - Certain antidepressants (e.g., fluoxetine): can increase sedation and prolong half‑life.